8 citations
,
May 2023 in “Cureus” Secukinumab for psoriasis may cause hair loss.
3 citations
,
October 2020 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
3 citations
,
July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
3 citations
,
March 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
3 citations
,
May 2020 in “JAAD Case Reports” Two patients with psoriasis grew extra hair after using certain psoriasis medications.
1 citations
,
May 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” Certain gene variations are linked to alopecia areata.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Bimekizumab can improve scarring alopecia in severe psoriasis.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
April 2023 in “The Egyptian Journal of Hospital Medicine” Higher Interleukin 17A levels may indicate more severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Cholecystokinin may help reduce skin inflammation in psoriasis.
July 2016 in “Journal of Investigative Dermatology” R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.
November 2024 in “Journal of Investigative Dermatology” Secukinumab reduces immune activity in hidradenitis suppurativa skin.
April 2026 in “Inflammopharmacology” Punica granatum leaf extract may help treat skin fibrosis by reducing inflammation and oxidative stress.
78 citations
,
June 2021 in “Dermatology and Therapy” Future acne treatments should aggressively target inflammation to prevent scarring.
32 citations
,
October 2023 in “Biomedicines” PCOS causes inflammation regardless of body weight.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
November 2025 in “The Journal of Immunology” Different γδ T cell types have unique roles in causing alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Hair follicles are crucial for maintaining skin barrier function.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
343 citations
,
March 2016 in “Nature Communications” IL-17-producing γδ T cells help improve bone healing.